David Brennan announced earlier this year that he would step down from his executive role, at the same time that a reduction of 26% was announced in the company's first quarter profit figures. His resignation came after a period of sustained shareholder pressure regarding the company's poor performance.
AZ has informed Brennan that he must give up share awards valued at around GBP4.3m that he was due under company-based performance and investment plans. He has voluntarily opted out of a further bonus.
The former chief executive will still be in line for share awards from 2010, worth in the region of GBP1.5m.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia